*** Welcome to piglix ***

Lexicon Pharmaceuticals

Lexicon Pharmaceuticals
Public
Traded as NASDAQLXRX
Industry Pharmaceutical
Founded The Woodlands, TX, 1995
Headquarters The Woodlands, United States
Key people
Lonnel Coats, President and Chief Executive Officer
Brian P. Zambrowicz, EVP & Chief Scientific Officer
Jeffrey L. Wade, EVP of Corporate Development & Chief Scientific Officer
Alan J. Main, EVP of Pharmaceutical Research
Pablo Lapuerta, EVP of Clinical Development & Chief Medical Officer
James F. Tessmer, VP of Finance and Accounting
Number of employees
225 (2011)
Website www.lexpharma.com

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering and developing breakthrough treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Arthur T Sands, Ray B Webb and. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.

The company's clinical drug candidates include sotagliflozin (LX4211) for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl (LX1032) for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis.

Lexicon Pharmaceuticals was founded in September 1995 as a biotech venture of Baylor College of Medicine. The company went public in April 2000 with one of the largest initial public offerings in biotech history ($220 million). In June, 2001 Lexicon purchased a privately owned small chemical library synthesis company, Coelacanth Corporation in Princeton, New Jersey, which became the site for the company's small molecule and medicinal chemistry efforts. The company's original name was Lexicon Genetics Incorporated, but in 2007, the name changed to Lexicon Pharmaceuticals, Inc. to reflect a renewed focus on drug development.


...
Wikipedia

...